PDLI Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice.
Quick AnswerPDLI — AI-powered stock analysis.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
PDLI (PDLI) Healthcare & Pipeline Overview
What Are the Key Risks for PDLI?
Negative return on equity (-10.6%) — the business is not currently generating profit on shareholder capital.
- Insider selling — insiders were net sellers of roughly $2.9M recently.
Insider Activity
12 transactions · 0 purchases, 6 sales, 6 other transactions · 5 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for PDLI stands at -10.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -9.8%, showing how much profit it generates from its asset base. A current ratio of 6.87 indicates the company holds enough short-term assets to cover its near-term obligations.
PDLI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PDLI Latest News
No recent news available for PDLI.
PDLI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PDLI.
Price Targets
Wall Street price target analysis for PDLI.
PDLI MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PDLI; grades run from A+ (80-100) to F (below 30).
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.